{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:53:56Z","timestamp":1788778436637,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijrobp.2023.04.021","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T06:21:36Z","timestamp":1682403696000},"page":"387-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non\u2013Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)"],"prefix":"10.1016","volume":"117","author":[{"given":"Rui","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiMei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KangQiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YiFeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DaQuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FangJie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NaiBin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinYu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuMing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-3756","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.04.021_bib0001","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential versus concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0002","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1200\/JCO.2016.69.9678","article-title":"Concurrent chemotherapy and radiation therapy for inoperable locally advanced non-small-cell lung cancer","volume":"35","author":"Rosenzweig","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0003","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0004","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0006","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0007","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2005.07.967","article-title":"Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: Impact of tumor volume","volume":"64","author":"Basaki","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0360-3016(01)01772-2","article-title":"Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma","volume":"52","author":"Bradley","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0009","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ijrobp.2020.10.021","article-title":"Adaptive radiation therapy (ART) strategies and technical considerations: A state of the ART review from NRG Oncology","volume":"109","author":"Glide-Hurst","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0011","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/bjc.2013.466","article-title":"Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: A randomised trial by the Norwegian Lung Cancer Study Group","volume":"109","author":"Str\u00f8m","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0012","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2021.06.032","article-title":"Concurrent chemoradiation therapy with or without nimotuzumab in locally advanced squamous cell lung cancer: A phase 2 randomized trial","volume":"111","author":"Qiu","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0013","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41598-021-04601-0","article-title":"Risk factors for radiation pneumonitis after rotating gantry intensity-modulated radiation therapy for lung cancer","volume":"12","author":"Tatsuno","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0014","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0015","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.21037\/tlcr-20-253","article-title":"Dose and fractionation schedules in radiotherapy for non-small cell lung cancer","volume":"10","author":"Kepka","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"suppl 21","key":"10.1016\/j.ijrobp.2023.04.021_bib0016","doi-asserted-by":"crossref","first-page":"S2465","DOI":"10.21037\/jtd.2018.01.153","article-title":"Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer","volume":"10","author":"Roach","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0017","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jtho.2022.01.006","article-title":"Improving outcomes in NSCLC: Optimum dose fractionation in radical radiotherapy matters","volume":"17","author":"Brada","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0018","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2022.01.012","article-title":"Phase I study of accelerated hypofractionated proton therapy and chemotherapy for locally advanced non-small cell lung cancer","volume":"113","author":"Contreras","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0019","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2020.03.015","article-title":"Hypofractionated proton therapy with concurrent chemotherapy for locally advanced non-small cell lung cancer: A phase 1 trial from the University of Florida and Proton Collaborative Group","volume":"107","author":"Hoppe","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant chemotherapy and radiotherapy with SBRT boost for unresectable stage III non-small cell lung cancer: A phase I study","volume":"12","author":"Higgins","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0021","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated intensity modulated radiation therapy with concurrent chemotherapy in locally advanced non-small cell lung cancer: A phase II prospective clinical trial (GASTO1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0022","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cllc.2014.08.002","article-title":"Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: A systematic review of the literature","volume":"16","author":"Kaster","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0024","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG Oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/COC.0b013e3181ec63ae","article-title":"Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer","volume":"34","author":"Lanni","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0026","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0027","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision hypofractionated radiation therapy in poor performing patients with non-small cell lung cancer: Phase 1 dose escalation trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0029","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0030","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ijrobp.2020.03.038","article-title":"Survival and toxicity of hypofractionated intensity modulated radiation therapy in 4 Gy fractions for unresectable stage III non-small cell lung cancer","volume":"107","author":"Kong","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0031","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2020.04.001","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement","volume":"146","author":"Guckenberger","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0032","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0033","doi-asserted-by":"crossref","first-page":"8548","DOI":"10.1200\/JCO.2021.39.15_suppl.8548","article-title":"NRG-RTOG 1106\/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC\u2014Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation)","volume":"39","author":"Kong","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0034","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0036","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0167-8140(99)00093-6","article-title":"A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial","volume":"52","author":"Ball","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0037","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.radonc.2016.07.013","article-title":"Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications","volume":"120","author":"Popp","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3857\/roj.2013.31.1.34","article-title":"Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemoradiotherapy of non-small cell lung cancer","volume":"31","author":"Park","year":"2013","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.11.1209","article-title":"Alterations in pulmonary function tests predict the development of radiation-induced pneumonitis in advanced NSCLC","volume":"12","author":"Arrieta","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","article-title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0041","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0042","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1172\/JCI57990","article-title":"A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1","volume":"122","author":"Pillay","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0043","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1038\/srep12493","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: A meta-analysis","volume":"5","author":"Gu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0044","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13277-015-3888-y","article-title":"Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer","volume":"37","author":"Cho","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ijrobp.2023.04.021_bib0045","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162300384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162300384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T12:02:55Z","timestamp":1725105775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162300384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S036030162300384X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.021","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non\u2013Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}